1.
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
by Coles, Alasdair J, Dr
The Lancet (British edition), 2012, Vol.380 (9856), p.1829-1839
2.
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
by Eggermont, Alexander M M, Prof
The lancet oncology, 2015, Vol.16 (5), p.522-530
3.
Key roles of adjuvants in modern vaccines
by Reed, Steven G
Nature medicine, 2013, Vol.19 (12), p.1597-1608
4.
The mechanism of action of MF59 – An innately attractive adjuvant formulation
by O’Hagan, D.T
Vaccine, 2011, Vol.30 (29), p.4341-4348
5.
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
by Cohen, Jeffrey A, Prof
The Lancet (British edition), 2012, Vol.380 (9856), p.1819-1828
6.
International consensus on allergy immunotherapy
by Jutel, Marek, MD
Journal of allergy and clinical immunology, 2015, Vol.136 (3), p.556-568
8.
Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study
by Gray, Richard
The Lancet (British edition), 2007, Vol.370 (9604), p.2020-2029
9.
CpG DNA as a vaccine adjuvant
by Bode, Christian
Expert review of vaccines, 2011, Vol.10 (4), p.499-511
10.
Maternal immunisation with trivalent inactivated influenza vaccine for prevention of influenza in infants in Mali: a prospective, active-controlled, observer-blind, randomised phas...
by Tapia, Milagritos D, MD
The Lancet infectious diseases, 2016, Vol.16 (9), p.1026-1035
11.
Effectiveness of MF59-adjuvanted seasonal influenza vaccine in the elderly: A systematic review and meta-analysis
by Domnich, Alexander
Vaccine, 2016, Vol.35 (4), p.513-520
12.
A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis -specific T-cell responses in human
by van Dissel, Jaap T
Vaccine, 2014, Vol.32 (52), p.7098-7107
13.
Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity
by Flach, Tracy L
Nature medicine, 2011, Vol.17 (4), p.479-487
14.
Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials
by Kreimer, Aimée R, Dr
The lancet oncology, 2015, Vol.16 (7), p.775-786
15.
Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity
by Morel, Sandra
Vaccine, 2011, Vol.29 (13), p.2461-2473
16.
Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: A randomized clinical trial
by Bernstein, David I
Vaccine, 2015, Vol.34 (3), p.313-319
17.
Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial
by Griffiths, Paul D, Prof
The Lancet (British edition), 2011, Vol.377 (9773), p.1256-1263
18.
Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes
by Calabro, Samuele
Vaccine, 2010, Vol.29 (9), p.1812-1823
19.
Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion
by Garçon, Nathalie
Expert review of vaccines, 2012, Vol.11 (3), p.349-366
20.
Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of t...
by Wheeler, Cosette M, Dr, Prof
The lancet oncology, 2012, Vol.13 (1), p.100-110
